Replies to post #97516 on Biotech Values

[drbio45]

this was an error in my last post. This refers to jerini's product

Firazyr causes a bee-sting like reaction. docs know it missed the primary endpoint in the randomized trial and Shire is having difficulty even recruiting patients.


-------------------------------------------------------------

regarding csl and viropharma

Parents and docs are reluctant to use a pooled plasma version when a pure human recombinant version of the same is available with better efficacy.

Look what happened to the Factor VII and insulin markets when the pure human proteins were made available. The market switched completely over to the pure human recombinant version.

[rkrw]

Why would you think Rhucin works in laryngeal attacks and Cinryze or Berinert doesn't. What basis do you have for claiming Rhucin works better? You realize all are C1 esterase don't you?

"Pooled plasma" C1 has been on the market for a few decades or so. No one has a problem with it. It's extremely effective and safe.

<<At investigator meetings no one wanted to use pooled plasma,>>>

Were you actually at the investigator meetings? Or is that what Pharming told you?

Maybe it will be approved, maybe not, but I still don't think end user sales are going to amount to all that much in HAE.